ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
86.8%−13.2 pts over 5 years
Operating margin
-18.9%+4736.1 pts over 5 years
Net margin
-31.7%+5993.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +98.0% | +141.4% | +153.0% | +56.6% | |
| Gross profit | +95.8% | +152.1% | +145.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -50.6% | -18.4% | |
| Current ratio | 13.67 | 14.02 | 1.04 | |
| Interest coverage | -23.4× | -4.1× | -0.7× | |
| Inventory turnover | – | – | 0.3× | |
| Capex to revenue | 14.6% | 285.6% | – | |
| Diluted shares | 27M | 51M | 61M |
Cash use needs five years of cash flow figures
Ascendis Pharma A/S does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-€228.03M
- Cash generatingOperating cash flow above zero€53.90M
- Return on assets improvedROA up on the prior year-45.8% → -19.3%
- Earnings backed by cashOperating cash flow above net income€53.90M vs -€228.03M
- Less leverageLong-term debt to assets fell31.0% → 29.6%
- Better liquidityCurrent ratio rose1.17 → 1.04
- No dilutionShare count did not rise58M → 61M
- Gross margin improvedGross margin up on the prior year87.83% → 86.82%
- More efficientAsset turnover rose0.44 → 0.61